Receptor signaling as a regulatory mechanism of DNA repair

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 316-322

  Meyn, Raymond E ^a   Munshi, Anapama ^a   Haymach, John V ^a   Milas, Luka ^a   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DNA repair; Radiosensitivity; Receptor tyrosine kinases; Tyrosine kinase inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN TYROSINE KINASE; TYRPHOSTIN;

CANCER CELL CULTURE; CELLULAR DISTRIBUTION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG INHIBITION; HUMAN; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

ANIMALS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOBIOLOGY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 69949134989     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.031     Document Type: Review

References (57)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N Engl J Med 345 (2001) 1890-1900
3. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8 (2001) 3-9
4. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
5. Camp E.R., Summy J., Bauer T.W., Liu W., Gallick G.E., and Ellis L.M. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005) 397-405
6. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12 (2006) 7242-7251
7. Ang KK, Mason KA, Meyn RE, Milas L. Epidermal growth factor receptor (EGFR) and its inhibition in radiotherapy. In: Kogelnik HD, Lukas P, Sedlmayer F, editors. 7th international meeting on progress in radio-oncology ICRO/PGRO, Salzburg, Austria: Medimond, Inc.; 2002. p. 557-67.
8. Sartor C.I. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 1 (2004) 80-87
9. Carracedo A., and Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27 (2008) 5527-5541
10. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
11. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
12. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
13. Harari P.M., and Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol 16 (2006) 38-44
14. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
15. Friedmann B.J., Caplin M., Savic B., et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 5 (2006) 209-218
16. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 (2005) 31182-31189
17. Shintani S., Li C., Mihara M., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107 (2003) 1030-1037
18. Toulany M., Kasten-Pisula U., Brammer I., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12 (2006) 4119-4126
19. Chinnaiyan P., Huang S., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65 (2005) 3328-3335
20. Helleday T., Lo J., van Gent D.C., and Engelward B.P. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6 (2007) 923-935
21. van Gent D.C., and van der Burg M. Non-homologous end-joining, a sticky affair. Oncogene 26 (2007) 7731-7740
22. Khanna K.K., and Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27 (2001) 247-254
23. Bandyopadhyay D., Mandal M., Adam L., Mendelsohn J., and Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273 (1998) 1568-1573
24. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76 (2005) 157-161
25. Das A.K., Sato M., Story M.D., et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66 (2006) 9601-9608
26. Das A.K., Chen B.P., Story M.D., et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 67 (2007) 5267-5274
27. Tanaka T., Munshi A., Brooks C., Liu J., Hobbs M.L., and Meyn R.E. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 14 (2008) 1266-1273
28. Li L., Wang H., Yang E.S., Arteaga C.L., and Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 68 (2008) 9141-9146
29. Yacoub A., Park J.S., Qiao L., Dent P., and Hagan M.P. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol 77 (2001) 1067-1078
30. Brem R., and Hall J. XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res 33 (2005) 2512-2520
31. Yacoub A., McKinstry R., Hinman D., Chung T., Dent P., and Hagan M.P. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159 (2003) 439-452
32. Toulany M., Dittmann K., Fehrenbacher B., Schaller M., Baumann M., and Rodemann H.P. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst) 7 (2008) 1746-1756
33. Ko J.C., Hong J.H., Wang L.H., et al. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol Cancer Ther 7 (2008) 3632-3641
34. Toulany M., Kehlbach R., Florczak U., et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7 (2008) 1772-1781
35. Golding S.E., Rosenberg E., Neill S., Dent P., Povirk L.F., and Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67 (2007) 1046-1053
36. Golding S.E., Morgan R.N., Adams B.R., Hawkins A.J., Povirk L.F., and Valerie K. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther (2009) 8
37. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
38. Chitnis M.M., Yuen J.S., Protheroe A.S., Pollak M., and Macaulay V.M. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14 (2008) 6364-6370
39. Guo A., Villen J., Kornhauser J., et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105 (2008) 692-697
40. Wen B., Deutsch E., Marangoni E., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85 (2001) 2017-2021
41. Allen G.W., Saba C., Armstrong E.A., et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67 (2007) 1155-1162
42. Peretz S., Jensen R., Baserga R., and Glazer P.M. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci USA 98 (2001) 1676-1681
43. Macaulay V.M., Salisbury A.J., Bohula E.A., Playford M.P., Smorodinsky N.I., and Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20 (2001) 4029-4040
44. Trojanek J., Ho T., Del Valle L., et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 23 (2003) 7510-7524
45. Lal B., Xia S., Abounader R., and Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11 (2005) 4479-4486
46. Chu S.H., Zhu Z.A., Yuan X.H., Li Z.Q., and Jiang P.C. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol 80 (2006) 143-149
47. Ganapathipillai S.S., Medova M., Aebersold D.M., et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Res 68 (2008) 5769-5777
48. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
49. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76 (2005) 162-167
50. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
51. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67 (2007) 568-572
52. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72 (2004) 257-266
53. Krause M., Schutze C., Petersen C., et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 74 (2005) 109-115
54. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83 (2007) 238-248
55. Rodemann H.P., Dittmann K., and Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83 (2007) 781-791
56. Zips D., Krause M., Yaromina A., et al. Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. J Pharm Pharmacol 60 (2008) 1019-1028
57. Astsaturov I., Cohen R.B., and Harari P.M. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 6 (2006) 691-710